Renal cell carcinoma treatment

A technology for renal cell carcinoma and patients, applied in the fields of peptide/protein components, drug combinations, organic active ingredients, etc., can solve problems such as compatibility problems and slow speed

Inactive Publication Date: 2002-09-04
SCHERING AG
View PDF13 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It must be noted that this response is slow and that 5 million IU interferon alfa-2b / m must be injected to achieve these results 2 , 3 times a week ("TIW")
In addition, interferon alfa-2b has many side effects that a large number of patients find unacceptable, and patient compliance with TIW injections of interferon alfa-2b has been problematic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0006] The present invention provides improved methods for treating patients suffering from RCC, especially metastatic RCC. The improved method provides a safer and more effective permissible treatment for RCC, which is pegylated by injection once a week alone or in combination with immunotherapeutics such as IL-2 or fluorouracil ("5-FU") Interferon alpha. RCC patients include patients newly diagnosed with the disease, as well as patients who are intolerant or anti-interferon alpha. The treatment with pegylated interferon alpha according to the present invention will last at least 6 months, and preferably at least 12 months, unless there is clinical evidence of disease progression, unacceptable toxicity or the patient requests to discontinue treatment.

[0007] When the administered pegylated interferon-α is pegylated interferon α-2b, the therapeutically effective amount of pegylated interferon α-2b is about 4.5 to about 9.0 μg / kg pegylated interference Alpha-2b, once a week (QW),...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a method of treating RCC patients who have not received or received treatment to obtain at least a partial tumor response, including administering a therapeutically effective amount of pegylated interferon alpha, such as pegylated alpha-2b, said interferon Use as a sole treatment or in combination with an effective amount of IL-2.

Description

Background of the invention [0001] The present invention relates to an improved therapy for the treatment of patients with renal cell carcinoma ("RCC"), wherein the treatment is achieved by administering a therapeutically effective amount of pegylated interferon-α within a time sufficient to obtain at least a partial tumor response. [0002] Metastatic renal cell carcinoma is usually resistant to chemotherapy with a single therapeutic agent or in combination. The use of immunotherapy, especially the use of interleukin-2 ("IL-2"), has been more successful. The use of high-dose intravenous IL-2 has achieved targeted tumor responses in approximately 14% of patients, some with long-term durability. Administration of high doses of IL-2 can cause capillary leak syndrome, resulting in hypotension and reduced organ perfusion. Such adverse effects can be serious and sometimes fatal. These toxicities generally limit the application of IL-2 to highly selected patients who are responsible for...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61K9/08A61K31/513A61K38/00A61K38/21A61K47/34A61P13/12A61P35/00
CPCA61K38/212A61K47/60A61P13/12A61P35/00A61P35/04A61K2300/00
Inventor E·H·罗斯M·E·赖巴克
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap